Only 1.5% of Africa’s population is fully vaccinated against COVID-19, but according to a recent FiercePharma article, that number is about to go up drastically. The U.S. is investing $200 million in an Aspen Pharmacare manufacturing facility in South Africa to boost the production of the Johnson & Johnson vaccine. The funds will allow the plant to increase capacity far beyond its current rate of 300 million doses per year. J&J has gone on record as saying it is providing its vaccine on a “not-for-profit basis” during the global pandemic, and pledged 500 million doses to the COVAX worldwide relief initiative last December.
U.S. Gives $200M to Boost Vaccines in Africa
The investment will increase production capacity of the J&J vaccine beyond its current rate of 300 million doses per year.
Jul 30, 2021
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
